Search details
1.
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.
Blood
; 131(24): 2661-2669, 2018 06 14.
Article
in English
| MEDLINE | ID: mdl-29724899
2.
A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer.
Invest New Drugs
; 33(1): 138-47, 2015 Feb.
Article
in English
| MEDLINE | ID: mdl-25248752
3.
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
Invest New Drugs
; 31(3): 751-9, 2013 Jun.
Article
in English
| MEDLINE | ID: mdl-23054212
4.
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
Invest New Drugs
; 31(4): 891-9, 2013 Aug.
Article
in English
| MEDLINE | ID: mdl-23135778
5.
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
Invest New Drugs
; 31(4): 927-36, 2013 Aug.
Article
in English
| MEDLINE | ID: mdl-23179337
6.
Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer.
Xenobiotica
; 43(5): 443-53, 2013 May.
Article
in English
| MEDLINE | ID: mdl-23548165
7.
A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors.
Invest New Drugs
; 30(4): 1566-74, 2012 Aug.
Article
in English
| MEDLINE | ID: mdl-21811833
8.
Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors.
Oncologist
; 15(12): 1253-61, 2010.
Article
in English
| MEDLINE | ID: mdl-21147873
9.
The absolute bioavailability of oral vinorelbine in patients with solid tumors.
Cancer Chemother Pharmacol
; 56(6): 578-84, 2005 Dec.
Article
in English
| MEDLINE | ID: mdl-16001165
10.
A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.
Mol Cancer Ther
; 14(2): 461-9, 2015 Feb.
Article
in English
| MEDLINE | ID: mdl-25504632
11.
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib.
J Clin Pharmacol
; 55(4): 392-400, 2015 Apr.
Article
in English
| MEDLINE | ID: mdl-25449654
12.
A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
Cancer Chemother Pharmacol
; 51(1): 58-66, 2003 Jan.
Article
in English
| MEDLINE | ID: mdl-12497207
13.
Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma.
Cancer Chemother Pharmacol
; 72(1): 231-40, 2013 Jul.
Article
in English
| MEDLINE | ID: mdl-23715625
14.
Bayesian methods for pharmacokinetic/pharmacodynamic modeling of pazopanib-induced increases in blood pressure and transaminases.
J Clin Pharmacol
; 53(4): 377-84, 2013 Apr.
Article
in English
| MEDLINE | ID: mdl-23381662
15.
Initial exploration of oral pazopanib in healthy participants and patients with age-related macular degeneration.
JAMA Ophthalmol
; 131(12): 1595-601, 2013 Dec.
Article
in English
| MEDLINE | ID: mdl-24113783
16.
Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.
Cancer Chemother Pharmacol
; 71(6): 1635-43, 2013 Jun.
Article
in English
| MEDLINE | ID: mdl-23636448
17.
A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors.
Cancer Chemother Pharmacol
; 71(3): 565-73, 2013 Mar.
Article
in English
| MEDLINE | ID: mdl-23344712
18.
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
Clin Cancer Res
; 19(4): 900-8, 2013 Feb 15.
Article
in English
| MEDLINE | ID: mdl-23363814
19.
Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Clin Cancer Res
; 19(13): 3631-9, 2013 Jul 01.
Article
in English
| MEDLINE | ID: mdl-23653147
20.
Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.
Mol Cancer Ther
; 11(8): 1820-8, 2012 Aug.
Article
in English
| MEDLINE | ID: mdl-22679111